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 PERUBAHAN DALAM PENGAWALATURAN PUSAT DAN PERIFERI 
TIKUS DIABETIS TERARUH STREPTOZOTOSIN 
 
ABSTRAK 
 
 Perubahan reflek kardiovaskular dalam diabetis menyumbang kepada penambahan 
fikiran yang tidak sihat dan kematian kardiovaskular. Perubahan ini mungkin berlaku pada 
aras saraf aferen, baroreflek pusat atau saraf eferen dalam lingkungan baroreflek. Dengan 
menggunakan tikus diabetis teraruh streptozotosin, kajian semasa direkabentuk untuk: (1) 
memeriksa secara sistematik perubahan diabetis teraruh pada komponen-komponen saraf 
pelbagai dengan menyiasat saraf aferen reflek baroreseptor, sumbangan baroreflek pusat 
dalam medula rostral ventrolateral (RVLM) dan nukleus paraventrikular (PVN) dan taburan 
saraf penggiat (c-Fos) dalam reaksi pengaktifan baroreseptor; (2) menilai reaksi vaskular 
tikus ternyahsaraf diabetis dalam ketidakhadiran baroreflek; dan (3) memeriksa potensi 
mekanisma bersel dalam gegelung aorta terasing in vitro yang mungkin menyumbang 
kepada disfungsi vaskular. Keputusan reflek baroreseptor dalam tikus diabetis teraruh STZ 
menunjukkan bradikardia baroreflek menurun dalam fenilefrina (PE)-teraruh meningkatkan 
tekanan arteri manakala takikardia reflek tidak berubah dalam natrium nitroprusida (SNP)-
teraruh menurunkan tekanan arteri. Untuk menguji sumbangan baroreflek pusat, suntikan 
mikro dengan L-glutamat (1nmol dalam 100nL) menunjukkan perangsangan simpato. 
Manakala, suntikan mikro dengan GABA (50nM dalam 100nL) menunjukkan perencatan 
simpato dalam kawasan RVLM. Walaubagaimanapun, keputusan yang diperolehi tidak 
menunjukkan sebarang perbezaan antara kedua-dua kumpulan dan ini selaras dengan 
keputusan imunokimia c-Fos, yang menunjukkan bilangan saraf penggiat dalam NTS dan 
 xxiv
RVLM adalah sama. Ini terbukti yang kerosakan tidak disebabkan oleh saraf sensori 
baroreseptor. Tambahan pula, perangsangan farmakologi saraf glutamat dengan asid DL-
Homosistik (200mM dalam 100nL) dalam kawasan PVN menunjukkan kemelesetan ketara 
dalam kedua-dua MAP dan HR tikus diabetis seperti yang dilihat dalam metioda bikukulina 
(antagoni reseptor GABAA, 1mM dalam 100nL), tetapi tidak kepada hidrobromida 
musimol (agoni reseptor GABAA, 2mM dalam 100nL). Keputusan ini mungkin disebabkan 
oleh kelemahan kesan perencatan tonik saraf GABA ke atas perangsangan simpato saraf 
glutamat. HR tikus diabetis menunjukkan pengurangan ketara menandakan kemungkinan 
pengurangan dalam ganglia kardiak dan aktiviti saraf ganglia kardiak. Taburan saraf 
penggiat (c-Fos) dalam reaksi pengaktifan baroreseptor meningkat dalam saraf tunjang 
menandakan yang kedua-dua RVLM dan PVN mengarah saraf mereka ke saraf tunjang. 
Dalam model haiwan ternyahsaraf, perbezaan tekanan antara kedua-dua kumpulan hilang, 
manakala dalam haiwan tidak ternyahsaraf, tikus diabetis menunjukkan pengurangan ketara 
dalam MAP rehat. Penemuan ini mencadangkan yang pengurangan dalam MAP rehat 
dalam tikus diabetis sebelum ternyahsaraf disebabkan oleh perubahan dalam tona 
vasomotor simpatetic pusat kerana pengalihan aliran keluar simpatetik berkeputusan MAP 
yang sama dalam kedua-dua kumpulan. Penyumbangan fungsi NO lemah dan pengeluaran 
faktor pengecutan endotelium (EDCF) daripada endotelium meningkat dalam gegelung 
aorta terasing in vitro tikus diabetis. Disfungsi vaskular berlaku pada aras endotelium 
dan/atau otot licin vaskular. Umur dilihat sebagai faktor penyumbang yang kuat kepada 
bentuk pemecutan disfungsi vaskular.   
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CHANGES IN CENTRAL AND PERIPHERAL REGULATION OF 
STREPTOZOTOCIN-INDUCED DIABETIC RATS 
 
ABSTRACT 
 
Alterations of cardiovascular reflexes in diabetes contribute to the increased 
cardiovascular morbidity and mortality. These alterations may be mediated at the level of 
afferent nerves, central baroreflex or efferent nerves within the baroreflex circuitry. Using 
the streptozotocin (STZ)-induced diabetic rats, the current study was designed to: (1) 
examine systematically diabetes-induced alteration of the multiple neural components by 
investigating the afferent nerves of the baroreceptor reflex, contribution of the central 
baroreflex in the rostral ventrolateral medulla (RVLM) and paraventricular nucleus (PVN) 
and distribution of activated neurons (c-Fos) in response to baroreceptor activation; (2) 
evaluate the vascular responsiveness of the diabetic pithed rats in the absence of baroreflex; 
and (3) examine the potential cellular mechanisms in isolated in vitro aortic rings that may 
contribute to vascular dysfunction. Results of baroreceptor reflex in STZ-induced diabetic 
rats showed baroreflex-mediated bradycardia was decreased in phenylephrine (PE)-induced 
increases in arterial pressure whereas reflex tachycardia was preserved in sodium 
nitroprusside (SNP)-induced decreases in arterial pressure. To test for the contribution of 
central baroreflex, microinjection of L-glutamate (1nmol in 100nL) showed 
sympathoexcitation. Meanwhile, microinjection with GABA (50nM in 100nL) showed 
sympathoinhibition in the RVLM regions. However, the results obtained did not show any 
difference between both groups and this was in line with the result of c-Fos 
immunohistochemistry, which demonstrated that the number of activated neurons in the 
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NTS and RVLM was similar. It is evident that the damage was not due to baroreceptor 
sensory nerves. In addition, the pharmacological stimulation of glutamatergic neurons with 
DL-Homocysteic acid (200mM in 100nL) in the PVN region showed a significant 
depression in both MAP and HR of diabetic rats as observed in to bicuculline methiodide 
(GABAA receptor antagonist, 1mM in 100nL), but not to muscimol hydrobromide (GABAA 
receptor agonist, 2mM in 100nL). These results are suggestive of the attenuation of 
GABAergic tonic inhibitory action on glutamatergic sympathoexcitation. The HR of 
diabetic rats showed significant reduction indicating the possible reduction in the cardiac 
ganglia and cardiac ganglionic neuronal activity. The distribution of activated neurons (c-
Fos) in response to baroreceptor activation increased in the spinal cord indicating that both 
RVLM and PVN project their neurons to the spinal cord. In pithed animals model, the 
pressure difference observed between both groups was abolished, whereas in the non-
pithed animals, the diabetic rats showed a significant reduction in the resting MAP. These 
findings suggested that the reduction in resting MAP in diabetic rats before pithing is due to 
the alteration in the intrinsic sympathetic vasomotor tone as removal of sympathetic 
outflow results in similar MAP in both groups. The functional contribution of NO was 
attenuated and the production of endothelium-derived contracting factor (EDCF) from the 
endothelium was enhanced in isolated in vitro aortic rings of diabetic rats. The vascular 
dysfunction occurred at the level of the endothelium and/or vascular smooth muscle. Age is 
seen to be a strong contributing factor to the accelerated form of vascular dysfunction.  
CHAPTER ONE 
GENERAL INTRODUCTION 
 
1.1 Nervous system 
The nervous system is an organ system containing a network of specialized cells 
called neurons. The neurons coordinate the actions and transmit signals between 
different parts of its body. The nervous system is made up of the central and peripheral 
nervous system.  
 
1.1.1 Central nervous system 
The central nervous system (CNS) comprises of the brain and spinal cord. The 
CNS is an integrative and control centre of the whole body. Anatomically, the regions of 
the brain are subdivided into the cerebrum, diencephalon, brainstem and cerebellum. 
The cerebrum is made up of cerebral hemispheres and diencephalon and both form the 
forebrain. Meanwhile the brainstem consists of the midbrain, pons and medulla 
oblongata. The brain also contains four interconnected cavities, the cerebral ventricles, 
which are filled with cerebral spinal fluid (Widmaier et al., 2006; Tortora and 
Derrickson, 2006).  
The spinal cord lies within the bony vertebral column. In cross section, the 
central butterfly-shaped of gray matter is composed of interneurons, the cell bodies and 
dendrites of efferent neurons, the entering axons of afferent neurons and glial cells. The 
gray matter is surrounded by white matter, which consists of group of myelinated axons. 
Groups of afferent fibers enter the gray matter of the spinal cord from the peripheral 
nerves via the dorsal roots and their cell bodies in the dorsal root ganglia. On the other 
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hand, the axons of efferent neurons leave the spinal cord via the ventral roots. Both 
dorsal and ventral roots from the same level combine to form a spinal nerve on each side 
of the spinal cord (Widmaier et al., 2006; Tortora and Derrickson, 2006). 
 
1.1.2 Peripheral nervous system 
The peripheral nervous system (PNS) consists of sensory neurons, clusters of 
neurons called ganglia, and nerves connecting the rest of the body and to the CNS. 
These regions are all interconnected by means of complex neural pathways. The PNS 
has 43 pairs of nerves: 12 pairs of cranial nerves and 31 pairs of spinal nerves that 
connect with the spinal cord. The 31 pairs of spinal nerves are designated by the 
vertebral levels from which they exit: cervical (C1-C8), thoracic (T1-T12), lumbar (L1-
L5), sacral (S1-S5) and coccygeal (CO1) (Widmaier et al., 2006; Tortora and 
Derrickson, 2006).  
The PNS is divided into somatic and autonomic nervous system (ANS). Both the 
somatic and ANS consist of sensory nerve fibers (afferent) which propagate impulses 
from receptors to the CNS and motor nerve fibers (efferent) which conduct impulses 
from the CNS to effectors (Loewy and Spyer, 1990). The somatic motor neurons, which 
lead to muscle excitation, innervate the skin, joints, and skeletal muscles and they are 
made up of a single neuron between CNS and skeletal muscle. Meanwhile, the motor 
neurons of ANS (visceral motor) contain neurons that innervate the internal organs, 
blood vessels, and glands and they have two-neuron (connected by a synapse) between 
CNS an effector organ. It can either give excitation or inhibition. The first neuron has its 
cell body in the CNS. The synapse between the two neurons is outside the CNS in a cell 
cluster called the autonomic ganglion. The neurons between the CNS and the ganglia are 
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called preganglionic neurons whereas the neurons between the ganglia and the effector 
organ are known as postganglionic neurons (Loewy and Spyer, 1990; Guyenet 2006). 
The ANS itself consists of three parts: the sympathetic, parasympathetic and enteric 
nervous system. Both sympathetic and parasympathetic will be elucidated in this study. 
The enteric nervous system, a subsystem of the peripheral nervous system, functions 
independently in controlling the gastrointestinal system through its primary connection 
via the vagus nerve (Loewy and Spyer, 1990). 
 
1.2 Cardiovascular physiology 
 The cardiovascular system consists of the pulmonary circulation and the 
systemic circulation. The pulmonary circulation starts from the right ventricle, moves to 
the lungs and then returns to the left atrium. The systemic circulation starts from the left 
ventricle, moves to all peripheral organs and tissues and then returns to the right atrium. 
In the systemic circulation, the large artery leaves the left side of the heart through the 
aorta and the large vein enters the right side of the heart through superior vena cava and 
inferior vena cava. The microcirculation of the arteries and veins are arterioles, 
capillaries and venules (Brownley et al., 2000). 
 The heart receives a rich supply of sympathetic and parasympathetic nerve 
fibers. The sympathetic postganglionic fibers innervate the entire heart and release 
norepinephrine while the parasympathetics terminate mainly on cells found in the atria 
and release primarily acetylcholine. The receptors for norepinephrine on cardiac muscle 
are mainly beta-adrenergic whereas the receptors for acetylcholine are the muscarinic 
type (Brodde et al., 2001; Olshansky et al., 2008). 
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 Cardiac output (CO) is the volume of blood pumped by each ventricle, usually 
expressed in liters per minute. The cardiac output is determined by multiplying the heart 
rate (HR) and the stroke volume (SV). The heart rate is the number of beats per minute 
whereas the stroke volume is the blood volume ejected by each ventricle with each beat 
(Charkoudian et al., 2005). The beating of the heart is influenced by the nerves and 
hormones acting on the SA node. The sinoatrial (SA) node is a small group of 
conducting-system cells located in the right atrium near the entrance of the superior vena 
cava. The action potential spreads from the SA node throughout the atria and ventricles. 
Most of the parasympathetic and sympathetic postganglionic fibers end on the SA node. 
Parasympathetic (vagus) nerves cause a decrease in the heart rate, whereas activity in the 
sympathetic nerves causes an increase in the heart rate. Furthermore, epinephrine, the 
hormone liberated from the adrenal medulla, speeds the heart by acting on the same 
beta-adrenergic receptors in the SA node as norepinephrine released from neurons 
(Vaseghi and Shivkumar, 2008). 
 
1.2.1 The vascular system 
 The aorta and other systemic arteries have thick walls of elastic tissue and serve 
as low-resistance conduits and as pressure reservoirs for maintaining blood flow to the 
tissues during ventricular relaxation. Arterial pressure is generally recorded as 
systolic/diastolic. The maximal aortic pressure following ejection is termed systolic 
pressure (Psystolic). As the left ventricle is relaxing and refilling, the pressure in the aorta 
falls. The lowest pressure in the aorta, which occurs just before the ventricle ejects blood 
into the aorta, is named the diastolic pressure (Pdiastolic). The difference between systolic 
pressure and diastolic pressure is called the pulse pressure.  The mean arterial pressure 
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(MAP) is the diastolic pressure plus one-third of the pulse pressure (Mohrman and 
Heller, 2010).  
The sympathetic nervous system plays an essential role in the regulation of 
arterial blood pressure and keeps the blood vessels in a continual state of partial 
constriction called sympathetic tone (or vasomotor tone). The parasympathetic nervous 
system normally dominates the heart and activity levels of the digestive and urinary 
systems – these organs exhibit parasympathetic tone. The parasympathetic nervous 
system slows the heart but, the sympathetic division can override these effects during 
times of stress (Widmaier et al., 2006). 
 
1.2.2 Factors affecting the arteriolar pressure 
The sympathetic nerves innervate most arterioles via alpha-adrenergic receptors 
and cause vasoconstriction. In some situations, noncholinergic, nonadrenergic neurons 
which release nitric oxide or other noncholinergic vasodilators can also innervate the 
blood vessels. Some chemical inputs can act by stimulating the endothelial cells to 
release either vasodilators or vasoconstrictors which then act on the adjacent vascular 
smooth muscles to cause either relaxation or contraction. This will lead to vasodilation 
or vasoconstriction respectively (Toda and Okamura, 2003). 
Endothelium, the largest organ in the body, senses mechanical stimuli such as 
pressure and shear stress, and hormonal stimuli such as vasoactive substances. It has 
been known to release agents that regulate vasomotor function, trigger inflammatory 
processes and affect homeostasis. Besides synthesizing and releasing many vasoactive 
compounds that modulate vascular diameter and hence tissue blood flow, it plays an 
important role in maintaining the vascular tone and luminal diameter of a blood vessel. 
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Hence, the vascular homeostasis depends on the net balance of vasoconstrictor and 
vasodilator forces as expounded by Dandona and co-workers (2003). It is widely 
accepted that three main endothelium-derived relaxing factors (EDRF) that act on 
vascular smooth muscle cells are nitric oxide (NO) (Furchgott & Zawadzki, 1980); 
prostacyclin (PGI2) (Dusting et al., 1977) and endothelium-derived hyperpolarizing 
factors (EDHF)(Taylor & Weston, 1988; Komori and Vanhoutte, 1990; Luksha et al., 
2009; Jin et al., 2011).  Apart from EDRFs, endothelium is also a source of contracting 
factor namely endothelium-derived contracting factors (EDCF). Examples of the EDCF 
that are released by the endothelial cells in response to certain mechanical and chemical 
stimuli include endothelin-1 (ET-1), angiotensin II (Ang II), thomboxane A2, 
norepinephrine, serotonin and reactive oxygen species (ROS) (Schiffrin, 2001; Verma & 
Anderson, 2002). 
NO is synthesized from its precursor L-arginine by the enzyme NO synthase 
(NOS). The formation of NO requires calcium entry into the endothelium cells, oxygen, 
the cofactors NADPH, tetrahydrobiopterin (BH4), calmodulin, heme (Snyder and Bredt, 
1992; Knowles and Moncada, 1994; Toda et al., 2007). The NO diffuses from the 
endothelium to vascular smooth muscle to activate soluble guanylate cyclase which 
increases the levels of cGMP to resulting in relaxation of vascular smooth muscles 
(Mayhan, 2001). At the same time, cGMP inhibits the calcium entry into the cell 
resulting in reduction in the intracellular free Ca2+ concentration which prevents the 
Ca2+-dependent activation of myosin light-chain kinase and muscle contraction (Toda 
and Okamura, 2003). NO also produces relaxation of blood vessels by the activation of 
potassium channels (Mayhan, 2001). Three distinct isoforms of nitric oxide synthase 
have been identified (eNOS – identified in vascular endothelium, nNOS – soluble 
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enzyme and expressed in the brain, peripheral nerves, including parasympathetic 
postganglionic nerves innervating blood vessels namely nitrergic nerve and iNOS – 
cytokine-inducible isoform) (Toda et al., 2007). NOS activity has been demonstrated in 
central and peripheral sites throughout the cardiac autonomic nervous system, including 
the receptors and effectors of the baroreflex pathway (Chowdhary and Townend, 1999). 
The endogenous and exogenous application of vasoactive agonists appears to bind to 
specific receptors on endothelial cells to stimulate the synthesis or release of nitric oxide 
or nitric oxide-containing compound that causes relaxation of vascular smooth muscles 
through activation of soluble guanylate cyclase (Vanhoutte and Mombouli, 1996; Toda 
et al., 2007). 
Prostacyclin (PGI2) is the major metabolite of arachidonic acid produced by 
cyclooxygenase in endothelial cells (Dusting et al., 1977). It is produced in the 
endothelial cells from prostaglandins H2 (PGH2) by the action of the enzyme 
prostacyclin synthase. It prevents formation of the platelet plug involved in blood clot 
formation. It is also an effective vasodilator. Its half-life is of seconds and broken down 
into 6-keto-PGF1, which is a much weaker vasodilator. Prostacyclin-induced 
vasorelaxation involves the opening of one or more of types of potassium channels such 
as ATP-sensitive potassium channels (K-ATP), large conductance calcium-activated 
potassium channels (BKCa), inwardly rectifying potassium channels (KIR) and/or voltage 
activated potassium channels (KV) (Feletou and Vanhoutte, 2006).  
Endothelium-derived hyperpolazing factor (EDHF) is synthesized and released 
from endothelium but its exact nature is still controversial. It hyperpolarizes vascular 
smooth muscle cells and causes these cells to relax and blood vessel to dilate. There is 
evidence to indicate that it links to endothelium-dependent relaxation by opening K+ 
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channels in vascular smooth muscle. K+ hyperpolarizes the smooth muscle cells by 
activating inward rectifying potassium channels and/ or Na+/K+-ATPase, leading to 
relaxation in small arteries (Chen et al., 1988; Komori and Vanhoutte, 1990; Luksha et 
al., 2009). Furthermore, it has been reported that the contribution of EDHF to 
endothelium-dependent relaxations increases as the vessels size decreases (Tomioka et 
al., 1999; Luksha et al., 2009). 
 
 
 
 
 
 
 
 
8 
 
  
Figure 1.1 Mechanism of endothelium dependent relaxation showing the release of 
nitric oxide (NO), prostacyclin (PGI2) and endothelium derived hyperpolarising factor 
(EDHF) from the endothelium. Agonists act on specific endothelial cell receptors and 
may stimulate the release of one or all mediators to induce smooth muscle relaxation. 
Abbreviations: Acetylcholine (ACh), histamine (Hist), endothelin-1 (ET-1), bradykinin 
(BK), substance P (Sub P), calcitonin gene related peptide (CGRP), nitric oxide synthase 
(NOS), arachidonic acid (AA), L-NG monomethyl arginine (L-NMMA), L-
NGnitroarginine methylester (L-NAME), haemoglobin (Hb), glyceryl trinitrate (GTN), 
sodium nitroprusside (SNP), 3-morpholinosydnonimine (SIN-1), methylene blue (Meth 
blue), cyclic guanosine/adenosine monophosphate (cGMP/cAMP), guanosine/adenosine 
triphosphate (GTP/ATP), non-adrenergic non-cholinergic (NANC), muscarinic receptor 
(M), histamine receptor (H1/2 ), endothelin B receptor (ETB ), bradykinin receptor (B2 ).  
(Buckley et. al., 1997). 
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1.3 Baroreceptor reflexes 
Arterial baroreceptor reflexes play an important role in homeostasis adjustments 
to mean arterial pressure by preventing large fluctuations of arterial blood pressure (BP), 
by rapidly adjusting cardiac output and total peripheral resistance. They utilize mainly 
changes in the activity of the autonomic nerves (i.e. sympathetic and parasympathetic 
nervous system) supplying the heart and blood vessels, as well as changes in the 
secretion of the hormones (epinephrine, angiotensin II and vasopressin) through their 
effects on heart rate, venous return, contractility and peripheral resistance (Rovere and 
Raczak, 2006). 
The heart and arterioles are controlled by sensory signals detecting changes in 
arterial pressure and pH (i.e. pCO2 and pO2) which modulate blood chemistry. Stretch-
sensitive mechanoreceptors in the blood vessels serve as arterial baroreceptor that relay 
information about arterial blood pressure and blood volume through the 
glossopharyngeal nerve (from carotid sinus) and vagus nerve (from aortic arch) whose 
cell bodies lie within the nodose ganglion. Both afferent neurons travel from the carotid 
sinus and aortic arch through the IXth and Xth cranial nerves to the brainstem and 
provide excitatory input to secondary baroreceptor sensory neurons in the nucleus 
tractus solitarii (NTS) (Skrapari et al., 2006). 
 
1.4 Central nervous mechanisms contributing to cardiovascular control 
Cardiovascular homeostasis involves the regulation of sympathetic vasomotor 
tone to maintain blood plasma volume and arterial blood pressure (Guyenet, 2006). The 
PVN is primarily concerned with blood volume regulation (Lovick and Coote, 1988) and 
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the rostral ventrolateral medulla (RVLM) is the dominant brain region for tonic 
regulation of arterial blood pressure (Dampney, 1994; Sved, 2004). 
The primary integrating center for the baroreceptor reflexes is called the 
medullary cardiovascular center which is located in the brainstem medulla oblongata. 
The central axons of the vagus and glossopharyngeal nerves terminate in the NTS in the 
posterior medulla. The fibers from NTS pass to the cardio-inhibitory and vasomotor 
centers of the medullary reticular formation, via a multisynaptic pathway involving an 
excitatory (glutamatergic neurons) projection from NTS to the caudal ventrolateral 
medulla (CVLM), an inhibitory (GABAergic neurons) projection from CVLM to the 
rostral ventrolateral medulla (RVLM) and an excitatory (glutamatergic) projection from 
RVLM to sympathetic preganglionic neurons via the intermediolateral cell column 
(IML) of the spinal cord (Dampney et al., 2003). These centers are also connected to the 
dorsal motor nucleus of the efferent vagal nerves, where parasympathetic outflow is 
regulated. Direct projections to the IML of the spinal cord originate predominantly from 
at least five areas of the brain: a) rostral ventrolateral medulla (RVLM), which plays a 
principal role in determining basal sympathetic nerve activity by balancing both 
inhibitory and excitatory inputs (Campos et al., 2008); b) rostral ventromedial medulla, 
c) caudal raphe nuclei, d) A5 cell group in the pons, and e) paraventricular nucleus of 
the hypothalamus (PVN)(Strack et al., 1989) and recently caudal pressor area 
(CPA)(Campos et al., 2008). 
During cardiovascular reflexes, a rapid increase in arterial blood pressure results 
in increased afferent nerves to the vagal cardio-inhibitory center, which sends out 
impulses to the heart resulting in vagal slowing. At the same time, the sympathetic 
vasomotor center is inhibited, resulting in reduction of sympathetic vasoconstrictor tone. 
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On the other hand, decreasing arterial blood pressure is compensated by sympathetic 
excitation, with a consequent rise in cardiac output and vasoconstriction. Sympathetic 
stimulation also passes to the spleen and kidneys to increase blood volume. The spleen 
capsule contracts to release more blood into the circulation. At the same time, renin is 
released from the kidney to activate the renin-angiotensin-aldosterone system to promote 
water retention. 
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Figure 1.2 Cardiovascular autonomic control and baroreflex integration (Chowdhary 
and Townend, 1999). ICNs are intracardiac neurons. 
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1.4.1 Rostral ventrolateral medulla (RVLM)  
 RVLM is located 0-500 µm caudal to the facial motor (VII) nucleus, lateral to 
the inferior olivary nucleus and ventral to the compact formation of the nucleus 
ambiguous (Stocker et al., 2007; Kashihara et al., 2008). RVLM is involved in the 
modulation of arterial blood pressure through a variety of cardiovascular reflexes 
(Guyenet, 1990; Dampney, 1994; Reis et al., 1994; Lipski et al., 1996). It contains 
neurons that exert some control on the cardiovascular system in a manner that an 
electrical or chemical stimulation in this region can evoke large pressor responses 
(Leman et al., 2000). The pressor responses are mediated by activation of sympathetic 
preganglionic neurons (SPN) mainly located in the intermediolateral nucleus (IML) of 
the spinal cord between segments C8 to L3-L5 (Janig, 1985; Laskey and Polosa, 1988; 
Cabot, 1990). The properties of the sympathoexcitatory neurons in the RVLM are 
influenced by baroreceptor signals and have been extensively investigated (Dampney, 
1994). 
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Figure 1.3 Schematic representation of pathways lead to the sympathetic vasomotor 
tone. RVLM = rostral ventrolateral medulla; CVLM = caudal ventrolateral medulla; 
NTS = nucleus of the tractus solitarius; IML = intermediolateral column; NA = nucleus 
ambiguous. Dotted line = GABAergic projection; continuous line = glutamatergic 
projection; dash-dot line = cholinergic projections (Modified from Campos et al., 2008). 
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1.4.2 The paraventricular nucleus (PVN) and cardiovascular control 
Smith (1965) was first drawn to the existence of direct projection of fibers from 
the hypothalamus to the autonomic regions of the spinal cord by electrolytic lesions at 
sites in the hypothalamus, which on prior stimulation had elicited pressor and 
cardioacceleratory responses. Anterograde neuronal labeling studies revealed that there 
are groups of neurons with axons projecting directly to the spinal cord and terminating 
in the sympathetic lateral horn (Sawchenko & Swanson, 1982; Coote, 2004a).  
The hypothalamic PVN is known to be involved in coordination of autonomic 
function such as regulation of food intake, responses to stress, modulating metabolic 
rate, thermoregulation and regulation of cardiovascular function (Schlenker, 2005). In 
addition, it influences neuroendocrine function and the secretion of vasopressin, 
thyrotropin-releasing hormone (TRH), orexin, corticotrophin-releasing factor (CRF) and 
oxytocin (Benarroch, 2005). It receives inputs directly or indirectly from rostral brain 
regions, including limbic system and amygdala and caudal brain stem regions such as 
NTS, pons, rostral ventrolateral medulla (RVLM) and locus coeruleus (Schlenker, 
2005).  
Anatomically, PVN is located on either side of the third ventricle in the 
hypothalamus. The PVN contains many different subgroups based on morphology and 
neuroanatomic projections. The subgroups are composed of magnocellular and 
parvocellular neurons. The magnocellular neurons project to the posterior pituitary and 
are responsible for secreting vasopressin (AVP) and oxytocin into the blood. The 
parvocellular PVN contains neurons that project to the intermediolateral cell column of 
the thoraco-lumbar spinal cord (IML) and neurons that innervate the pressor region of 
the RVLM (Badoer, 2001). The latter neurons are known to influence sympathetic nerve 
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activity. Accumulating evidence support that these neurons in the PVN can: (i) directly 
influence sympathetic nerve activity (via PVN-IML connections); (ii) indirectly 
influence sympathetic nerve activity (via PVN-RVLM connections); and (iii) both 
directly and indirectly influence sympathetic nerve activity (Dampney, 1994; Coote et 
al., 1998; Pyner and Coote, 2000; Badoer, 2001). The PVN is innervated by the A1 and 
A2 cell groups (Kannan et al., 1987) and receives afferent connections from peripheral 
baroreceptors. 
The magnocellular neurons of the PVN play a key part in neuroendocrine control 
of fluid balance. The vagus nerve sends an impulse from atrial volume receptors located 
at the venous-atrial junctions to the brain. The first synapse is within the NTS of the 
medulla oblongata. The volume signals travel from the NTS to the hypothalamus to 
influence neurons in the PVN (Lovick and Coote, 1988; Pyner et al., 2002). Deering and 
Coote (2000) demonstrated that low amount of neurons excitant DL-Homocysteic acids 
preferentially evoke excitation of cardiac sympathetic activity and simultaneously evoke 
inhibition of renal sympathetic activity. 
The most recent method in which excitatory amino acids are microinjected into 
the area of interest has overcome the disadvantage of electrical stimulation by 
selectively stimulating the cell bodies of interest (Goodchild et al., 1982). The changes 
in blood pressure and sympathetic nerve activity were reported to either decrease or 
increase when PVN was stimulated (Kannan et al., 1987, Malpas and Coote, 1994). 
Subsequently, Schlenker et al., (2001) reported that unilateral microinjection of 
bicuculline, a γ-aminobutyric acid GABAA receptor antagonist, into the PVN of 
conscious rats increased mean arterial pressure (MAP), breathing frequency, increased 
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the volume of a breath, heart rate and oxygen consumption for up to 10 minutes 
following injection.  
 
1.4.3 Neurotransmitters in central cardiovascular regulation: Glutamate and 
GABA 
 Amino acid L-glutamate (GLU) is the major excitatory neurotransmitter in the 
mammalian central nervous system, whereas, γ-aminobutyric acid (GABA) appears to 
be the principal neurotransmitter mediating inhibitory synaptic currents. Both GLU and 
GABA play predominant roles in brainstem and spinal circuits that are essential for 
control of cardiovascular function by the CNS (Gordon and Sved, 2002).  
 Many experimental techniques have been used to explore the role of GLU and 
GABA in central pathways controlling cardiovascular function. Pharmacological studies 
involving direct microinjections of drugs into specific brainstem regions have been a 
continuous motivation among researchers since the last century. Microinjections of GLU 
and GABA were not only utilized to study neurotransmitters but also used to aid in the 
activation or inhibition of cells in a specific brain region.  
The synaptic inputs to RVLM neurons are excitatory or inhibitory. These inputs 
are generally mediated via glutamate or GABA receptors. However, the RVLM 
presympathetic neurons also present receptors for other neurotransmitters or 
neuromodulators such as angiotensin II, enkephalin or ATP (Dampney 1994). 
The PVN is a nucleus to which a number of excitatory and inhibitory 
neurotransmitters converge to influence its neuronal activity. The inhibition is dependent 
on GABA, which is mostly mediated by ionotropic GABAA receptors and NO. NO 
potentiates local GABAergic synaptic inputs onto the neurons in the PVN. Glutamate 
18 
 
and angiotensin II are excitatory neurotransmitters which modify the tonic inhibitory 
activity. Other neurotransmitters which have been shown to affect cardiovascular 
function are oxytocin, vasopressin and dopamine. They are found in neurons of the PVN 
and within the spinal cord (Pyner, 2009)  
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Figure 1.4 Schematic diagram illustrating the three main pathways by which the 
paraventricular nucleus of the hypothalamus (PVN) can influence sympathetic activity. 
A direct descending projection (blue) to the spinal intermediolateral cell column (IML); 
a projection to the vasomotor neurones (red) of the rostral ventrolateral medulla 
(RVLM) and a collateral projection to both RVLM and IML (green). In addition, the 
inset summarises the distribution of the neurotransmitters discussed: the parvocellular 
subdivisions of the PVN contain neurones capable of synthesising vasopressin (VP), 
oxytocin (OT), dopamine (DA), angiotensin II (ANG II) and nitric oxide (nNOS), 
although the majority of nitric oxide synthesising neurones are found in the 
magnocellular subdivision. Putative interneurones surrounding the PVN that contribute 
to the regulation of parvocellular neuronal activity contain GABA, glutamate (GLU) and 
nNOS (adapted from Pyner, 2009). 
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1.5 c-Fos immunohistochemistry 
  The early techniques that was used to metabolically identify regions of the brain 
that were involved in specific functions was the use of 2-deoxyglucose (2DG)(Kennedy 
et al., 1975). Following which, the histochemical localization of metabolic enzymes such 
as cytochrome oxidase and hexokinase has been used as a means to identify populations 
of neurons that respond to physiological stimuli (Krukoff, 1999). Although these 
techniques are inexpensive and technically straightforward there are limitations in their 
applications. The development of immediate-early genes described as c-Fos in neurons 
has provided a useful and popular marker of activated neurons. c-Fos encodes a protein 
(Fos) that participates with products of the related Jun family as a component of the 
protein complex that binds to the activator-protein-1(AP-1) binding site of DNA. Genes 
that contain AP-1 complex are activated by the Fos/Jun complex, thereby allowing the 
expression of the so-called late-onset genes that encode differentiated neuronal products 
such as neurotransmitters. Transcription of c-Fos occurs within minutes of application of 
a stimulus, amount of mRNA peaks at 30-45 minutes, and the half-life of the Fos protein 
is about 2 hours (Muller et al., 1984). In the central nervous system, basal levels of c-Fos 
immunoreactivity (ir) are low, but increase rapidly and transiently in response to 
stimulation (Krukoff, 1999). It has been suggested that c-Fos activation may be utilized 
as a high resolution metabolic marker for polysynaptic pathway tracing in the brain and 
spinal cord (Malakhova and Davenport, 2001). Fos immunohistochemistry stains the 
neuronal nucleus and detects neuronal changes (Dragunow and Faull, 1989).  
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1.6 Rational of the thesis 
To summarize, sympathetic vasomotor outflow consists of efferent pathways that 
control vascular tone (vascular peripheral resistance) and cardiac output (contractility 
and heart rate), playing an essential role in maintaining the balance of blood pressure 
and bodily homeostasis. The integration of autonomic outflow to the cardiovascular 
system and the vasomotor tone is dependent on the activity of neurons located within the 
medulla which exhibit both excitatory and inhibitory inputs. The PVN and the RVLM 
appear to have a tonic effect on the control of sympathetic vasomotor tone of the five 
nuclei mentioned earlier (Dampney, 1994; Pan, 2004) and baroreceptor reflex pathway 
has been a tool in the research on brainstem-spinal control of cardiovascular regulation 
and identified to have pronounced effect on cardiovascular system. 
Neurophysiology concerning the central and peripheral nervous system has been 
described to be an important issue in maintaining bodily homeostasis. However, the 
course of development of neurophysiology alterations such as CNS and PNS in STZ-
induced diabetic rats is incompletely documented. With regard to the matter, the 
framework of the present study will be focusing on the role of CNS and PNS in 
cardiovascular regulation in STZ-induced diabetic rats. These include the baroreceptor 
reflex circuitry at different time frame, pharmacological stimulation of glutamatergic 
and GABAergic neurons within the RVLM and PVN regions and neuroanatomical 
changes during baroreceptor activation. Furthermore, an attempt was also made to study 
the vascular responsiveness in pithed animal model and vascular reactivity in in vitro 
aortic rings.  
 
 CHAPTER FOUR 
GENERAL CONCLUSION 
 
Diabetes mellitus can affect both the peripheral and the central nervous system. 
The nervous system plays an important role in regulating the cardiovascular functions. 
This study implicates both central and peripheral nervous system in cardiovascular 
regulation in diabetes.  Some of the important findings in this study can be summarized 
below: 
1. An impaired baroreflex-mediated bradycardia and preserved baroreflex-
mediated tachycardia was observed in diabetic rats. The baroreflex 
sensitivity decreased in diabetic rats. The impaired baroreflex sensitivity 
may be mediated at the level of afferent nerves, central baroreflex or 
efferent nerves. 
2. The pharmacological stimulation of excitatory neurons (glutamatergic 
neurons) with L-glutamate showed sympathoexcitation, whereas 
sympathoinhibition was seen when inhibitory neurons (GABAergic 
neurons) were activated with GABA at RVLM site. The results observed 
did not show any difference in these actions between non-diabetic and 
diabetic rats. However, the HR of diabetic rats showed significant 
reduction in both pharmacological stimulations. 
3. Pharmacological stimulation of glutamatergic neurons with DL-
Homocysteic acid showed significant reduction in both MAP and HR in 
diabetic rats. Similar results were obtained when stimulated with GABAA 
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receptor antagonist, bicuculine methiodide into the PVN, i.e.  significant 
reduction in sympathoexcitation, but not to GABAA receptor agonist, 
muscimol. These results may be due to the attenuation of GABAergic 
tonic inhibitory action on glutamatergic sympathoexcitation. 
4. Results of c-Fos immunohistochemistry showed that the numbers of 
baroreceptor activated c-Fos-ir neurons in the NTS and RVLM were 
similar between non-diabetic and diabetic rats indicating that it is not 
likely to be due to the damage to the baroreceptor afferent fibers of the 
CSN and ADN.  
5. In addition, the results of c-Fos immunohistochemistry also support the 
notion that RVLM and PVN project their neurons to the IML of the 
spinal cord directly and indirectly to influence sympathetic nerve activity 
since the c-Fos-ir neurons in the spinal cord are found to produce massive 
distribution during baroreceptor activation with PE. 
6. It is reasonable to suggest that there is impairment in the baroreflex 
pathway involved in the cardiovascular regulation in STZ-induced 
diabetic rats. 
7. In the second part of the study, a significant reduction in the resting MAP 
was observed in non-pithed diabetic rats, suggesting altered intrinsic 
sympathetic vasomotor tone as the removal of sympathetic outflow 
results in similar MAP in both groups. In addition, the functional 
contribution of NO is attenuated in pithed diabetic rats and an intact 
nervous system is not necessary for the synthesis and release of EDRF. 
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8. The depression in vascular responsiveness to PE and an impaired 
synthesis of NO were observed in pithed diabetic rats. Other EDRF such 
as prostacyclin and EDHF may also play a role in the regulation of 
vasomotor tone. 
9. The potential cellular mechanisms that contribute to the vascular 
dysfunction in STZ-induced diabetic rats were also determined. It is 
suggested that the impairment occurred at the level of endothelium and/or 
vascular smooth muscle. 
10.  Time is also the primary contributing factor to the accelerated form of 
vascular dysfunction. 
11. Finally, an understanding of mechanisms that leads to impaired reflex 
function and endothelial dysfunction will certainly lead to new and 
unique therapeutic strategies to reduce cardiovascular morbidity and 
mortality in diabetes mellitus. 
